Sign In
Buy ALNY
$272.67
+5.20 (+1.94%)
At Close: Jul 20, 2026
Alnylam Pharmaceuticals, Inc. $ALNY Stock Position Lifted by Fifth Third Bancorp
04:30am, Monday, 20'th Jul 2026
Fifth Third Bancorp grew its position in Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) by 7,433.9% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commiss
Alnylam Pharmaceuticals, Inc. $ALNY Shares Bought by Allspring Global Investments Holdings LLC
03:08am, Saturday, 18'th Jul 2026
Allspring Global Investments Holdings LLC grew its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) by 1.1% in the undefined quarter, according to its most recent filing with the SEC. The firm ow
Alnylam to Webcast Conference Call Discussing Second Quarter 2026 Financial Results
08:00am, Thursday, 16'th Jul 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter end
Alnylam Pharmaceuticals: Commercial Momentum Outweighs TTR Read-Through Concerns
05:44am, Thursday, 16'th Jul 2026
I initiate coverage of Alnylam Pharmaceuticals with a non-consensus BUY rating, citing the recent pullback as an overreaction. AMVUTTRA now holds a near-term commercial monopoly in TTR silencing, with
Alnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurological Disease
03:30am, Wednesday, 15'th Jul 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today shared advances across its growing neuroscience portfolio at the Alzheimer
The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions
12:25pm, Monday, 13'th Jul 2026
When a late-stage clinical trial misses a primary endpoint, the market reaction rarely distributes evenly across the board. The fallout often reveals undeniable fundamental truths about single-asset e
Jim Cramer Says Biotech is The Hottest Group in The Market Right Now
11:35am, Thursday, 09'th Jul 2026
CNBC's Jim Cramer pushed viewers away from the usual semiconductor and hyperscaler chatter.
AstraZeneca Stock and Partner Ionis Sink After Trial Failure. Alnylam Soars.
07:38am, Thursday, 09'th Jul 2026
AstraZeneca and California-based biotech Ionis Pharmaceuticals announce a late-stage trial failure for their gene silencing drug, Wainua.
Can Alnylam's Drug Pipeline Fuel Its Long-Term Revenue Growth?
12:56pm, Monday, 06'th Jul 2026
ALNY's advancing pipeline and partnered programs can expand future revenue sources alongside its growing portfolio of approved therapies.
Wall Street Thinks This Biotech Stock Can Soar 45%. Here's Why Analysts Are Right.
06:33am, Thursday, 02'nd Jul 2026
The company has six marketed therapies and several others in late-stage clinical trials. Alnylam has a unique drug delivery system that gives it a deeper moat.
Alnylam Pharmaceuticals, Inc. (ALNY) Discusses ALN-6400 RNAi Therapy Targeting Plasminogen for Rare Bleeding Disorders Transcript
05:12pm, Thursday, 25'th Jun 2026
Alnylam Pharmaceuticals, Inc. (ALNY) Discusses ALN-6400 RNAi Therapy Targeting Plasminogen for Rare Bleeding Disorders Transcript
Komodo Expands Strategic Partnership With Alnylam to Scale AI-Powered Intelligence Platform
09:00am, Thursday, 25'th Jun 2026
NEW YORK & SAN FRANCISCO--(BUSINESS WIRE)-- #AI--Komodo Health®, the leader in AI-powered healthcare intelligence, today announced an expanded strategic partnership with Alnylam Pharmaceuticals (Nasd
Can Alnylam's Broader Portfolio Ease Its Dependence on Amvuttra?
09:31am, Monday, 22'nd Jun 2026
Amvuttra is the primary driver of ALNY's revenues, but growth from Givlaari, Oxlumo and Leqvio may help diversify the company's top line.
The Healthcare M&A Wave
12:30pm, Wednesday, 17'th Jun 2026
In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.
Why Alnylam Pharmaceuticals (ALNY) is a Top Momentum Stock for the Long-Term
10:51am, Tuesday, 16'th Jun 2026
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
